Syntimmune approaches areas of high unmet medical need in a unique way.
Syntimmune focuses on areas of science that are well understood and extensively researched. We seek new treatments that build on these areas of scientific consensus and broad applicability.
In the case of our lead drug candidate, SYNT001, both the cellular pathway and the specific molecular target have been studied extensively for more than 25 years, spearheaded by the groundbreaking research of the scientific team behind Syntimmune.
In an industry that often places a premium on novelty, Syntimmune understands that creating real value comes from helping patients who are suffering with diseases for which current treatments are inadequate or nonexistent.